No Data
SymbolStock Name
Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
WatchlistPaper Trade
ThirtyOne : Agreed. It’s hard to even fathom the standards of being overvalued in this generation.
QMengColdJoke : if oral GLP-1 is good to go… Short LLY. Really fat people (fat cells doesn’t fell pain) and people with diabetes (get used to) don’t care to have needle hole. But think about 25 to 30 BMI people, Having needle holes would really be a concern
MonkeyGee OP QMengColdJoke : please explain. I don't trade based on company activities but based on stock trends.
QMengColdJoke MonkeyGee OP : Zepbound is much better than Wegovy/Ozempic in effectiveness. They used to have similar price like 1000 per month. Typically insurance only cover a ratio. LLY recently cuts to 400 to 600 per month. Liraglutide will be out of patent pretty soon that people can manufacture (but cannot sell as drug) That would cut revenue projection…
QMengColdJoke MonkeyGee OP : LLY is a great company. But wall street has made stock price way too expensive.